PromptDegrader™ Platform
Platform for IDR-protein driven diseases
Pre-clinicalActive
Key Facts
About RDP Pharma
RDP Pharma is a private, pre-clinical stage biotechnology company pioneering novel approaches to drug delivery and protein degradation. Its flagship technology, the PromptDegrader™ platform, is designed to rationally degrade disease-causing proteins with intrinsically disordered regions (IDRs), a class long considered undruggable. The company's pipeline includes programs targeting HPV-driven cancers (E7 Degrader), the MYC oncoprotein, and next-generation drug delivery modules, positioning it at the forefront of a challenging but high-potential therapeutic frontier. RDP is actively seeking development partners to advance its innovative portfolio.
View full company profile